Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 Antianemeic drugs Agents to Tr anemia Dr Alia Alshanawani.

Similar presentations


Presentation on theme: "1 Antianemeic drugs Agents to Tr anemia Dr Alia Alshanawani."— Presentation transcript:

1 1 Antianemeic drugs Agents to Tr anemia Dr Alia Alshanawani

2 2 Hematopoiesis: production of erythrocytes, platelets, & leukocytes from stem cells in ! Bone marrow. Require a constant supply of 3 essential nutrients: - Iron - Vitamin B 12 - Folic acid + hematopoietic growth factors. Anemia: deficiency in O 2 -carrying erythrocytes.

3 3 Anti-anemic drugs In iron deficiency & other hypochromic anemia: -Iron -Pyridoxine, Riboflavin, Copper In megaloblastic anemia: -Vit B 12 -Folic acid Hematopoietic GFs -Erythropoietin (in chronic renal failure).

4 4 Agents used to Tr anemia 1- Iron: Iron deficiency is ! most common cause of chronic anemia. Total Body Iron 4 g in ! adult male 2.5 g in ! adult female Source: meat & green vegetables.

5 5

6 6 Iron forms ! nucleus of ! iron-porphyrin heme ring, which together with globin chains forms Hg. Hg reversibly binds O 2 (delivery). Iron deficiency causes: small erythrocytes with insufficient Hg are formed: microcytic hypochromic anemia. PK : All of ! iron used to support hematopoiesis is reclaimed from catalysis of ! Hg in aged / damaged erythrocytes.

7 7 Dietary requirements are small & easily available in food. Iron absorption: Actively absorbed in duodenum & proximal jejunum. In ! ferric (+++) form & is complexed to other organic & inorganic molecules. ! acids in ! stomach & hydrolytic enzs in small intestine release ! iron from these complexes. It is then reduced to ! ferrous (++) form (more readily absorbed). Absorption is increased by: glucose, amino acids & ascorbic acid. & decreased by : phosphate bicarbonate bile acids, antacids & tetracycline. Heme iron in meat Hg & myoglobin can be absorbed intact. Iron in vegetables & grains, tightly bound to organic compounds; < available for absorption.

8 8 Excess iron: stored in mucosal cell as ferritin, a water-soluble complex. Distribution: Iron is transported in ! plasma bound to transferrin, a β globulin binds 2 molecules of ferrous iron. ! iron is transported to ! marrow for use /storage. ! transferrin-iron complex enters maturing erythroid cells by a specific R mechanism.

9 9 Storage: When free iron levels are high, apoferritin is produced to sequester iron & protect organs from toxic effect of excess free iron. Iron is stored in intestinal mucosal cells & as ferritin, in macrophages in liver, spleen, & bone.

10 10 A- Uses of iron: -Treatment of iron deficiency anemia -Prevent anemia in increased iron requirement: - premature infants, - children during rapid growth periods, - pregnant & lactating women, - increased blood losses & iron (heavy menstruation), - patients with chronic kidney disease & treatment with GF erythropoietin (parenteral iron is preferred). - Malabsorption, inadequate iron absorption, GIT bleeding, gastrectomy & severe small bowel disease.

11 11 B- Treatment Iron deficiency anemia is treated with po/ parenteral iron. po iron if GIT is normal. 1- Po iron: 200 – 400 mg for 3-6 months. Forms: FERROUS sulfate, gluconate, fumarate or succinate. All are effective & inexpensive.

12 12 SE: N, epigastric discomfort, abdominal cramps, constipation/ diarrhea & black stools. Treatment: lower ! dose/ taking ! tablet immediately after/ with meal.

13 13 2- Parenteral iron; used in ! Following cases: (postgasrectomy, small bowel section, inflammatory bowel disease, noncompliance of po, malabsorption syndrome, marked blood loss & advanced chronic renal disease). Iron dextran: stable complex of ferric hydroxide & low molecular weight dextran (IM/ IV infusion). Advantage of IV: eliminates local pain & tissue staining (SE: IM). + allow delivery of entire iron dose. Also Iron sorbitol (IM)

14 14 SE: headache, light-headness, fever, arthralgia, N, V, back pain, flushing, urticaria, Bronchospasm. Rare: anaphylaxis & death. Also dextran can cause hypersensitivity reactions. Alternative preparations: Iron-sucrose complex & iron Na + gluconate complex. ONLY (IV) less hypersensitivity than dextran.

15 15 A- Acute iron tox: (multiple blood transfusions /acute child iron poisoning) Signs & symptoms: Necrotizing gastroenteritis, V, abdominal pain, bloody diarrhea, followed by shock, lethargy, & dyspnea. + severe metabolic acidosis, coma & death. Treatment: -Whole bowel irrigation/ gastric lavage: 1% NaHCO 3. -Antidote: Deferoxamine (Desferroxamine), potent iron-chelating agent, bind absorbed iron & promote its excretion in urine & feces (intragastric, IM, SC, IV infusion).

16 16 B- Chronic iron tox: Overload / hemochromatosis, result when excess iron is deposited in ! heart, liver, pancreas, & other organs. It can lead to organ failure & death. Causes: patients with inherited hemochromatosis (excessive iron abs;; tissue damage), & iron overload in patients who receive many RBCs transfusions over a long period of time as chronic hemolytic, microcytic anemia (thalassemias).

17 17 Treatment tox: intermittent phlebotomy: Removing one unit of blood every week until all excess iron is removed. Or parenteral deferoxamine (less efficient, more complicated, expensive, & hazardous). Recent oral iron chelator: deferasirox. Effective as deferoxamine at reducing liver iron conc & more convenient.

18 18 2- Cyanocobalamin = Vitamin B 12 (extrinsic F) CoFactor for several essential biochemical reactions. Its Deficiency;; anemia, GI symptoms, & neurological abnormalities. Chemistry: porphyrin-like ring with a central cobalt atom & nucleotide. Source: Meat (liver), eggs, & dairy products. For therapeutic use: Cyanocobalamin & hydroxycobolamin.

19 19 PK: Stored mainly in liver Normal daily requirement: 2 -3 mcg. For its absorption, it makes a complex with intrinsic Factor, a glycoprotein secreted by ! parietal cells of ! gastric mucosa + R mediated transport system in ! lumen. Must be converted to active forms b4 absorption: Deoxy- adenosyl-cobalamin & methyl-cobalamin. Vit B 12 deficiency results from malabsorption due to lack/loss/ malfunction of intrinsic F. This intrinsic F may be absent in gastrectomy & pernicious (megaloblastic) anemia. Nutritional deficiency (rare). Route of administration: mainly: parenteral,, IM Or po/ aerosol. Excretion: kidney.

20 20 Pharmacodynamics: essential enzymatic rxs require Vit B12: Methylcobalamin: as intermediate in ! transfer of methyl gp from N-methylTHF to homocysterine, forming methionine & tetrahydrofolate (THFA). Required for purines & DNA synthesis. Depletion of THFA prevent ! synthesis of DNA. Treatment: Vit B12 + folic acid.

21 21

22 22

23 23 Clinical pharm: Features of Vit B12 deficiency: -Impaired DNA synthesis; mainly RBCs -Megaloblastic anemia (macrocytic anemia + leukopenia &/ thrombocytopenia) -Hematologic abnormalities -GI symptoms -Neurological syndrome: paresthesia & weakness in peripheral nerves, spasticity, & ataxia.

24 24 Causes of vit B12 deficiency: -Pernicious anemia (Defective secretion of intrinsic F by ! gastric mucosal cells). -Partial/ total gastrectomy -Malabsorption syndrome, inflammatory bowel syndrome or small bowel resection. -Damage of distal ileum that absorb vitB12- intrinsic F complex, -Surgical resection of ! ileum. TR: Vit B12.

25 25 Tr: parenteral inj of vit B12. Available as: 1-Cyanocobalamin 2-Hydroxycobolamin is preferred (more highly protein bound: longer duration). Uses: 1- Pernicious (Addison) anemia 2- Neurologic abnormalities 3- Gastrectomy 4- Cyanide poisoning; Hydroxyocobalamin will bind circulating & cellular cyanide molecules to form cyanocobalamin which is excreted in ! urine. cyanocobalamin

26 26 Initial therapy: 100-1000 mcg of vit B12 IM daily or every other day for 1-2 wks Maintenance: 100-1000 mcg IM once a month for life. Oral dose of 1000 mcg of vit B12 in pernicious anemia who refuse or cannot tolerate ! inj. After parenteral, ! vit can also administered as a spray/ gel.

27 27 Adverse effect of Vit B12 1- Allergic hypersensitivity reactions 2- Arrhythmia secondary to hypokalemia.

28 28 3- Folic acid (FA): Function: synthesis of amino acids, purines, pyrimidines, DNA & therefore cell division. Its deficiency is uncommon. deficiency of THFA causes anemia, congenital malformations in newborns & occlusive vascular D. Chemistry: FA is pteroglutamic acid, composed of pteridine, P-aminobenzoic acid + glutamic acid.

29 29

30 30 FA can undergo reduction, catalyzed by DHFRase>> dihydroFA >>HFA (active form). Vit B12 is required for activation of FA (demethylation). PK: Source (as polyglutamate form): yeast, liver, kidney, & green vegetables. 5-20 mg of folates are stored in liver. Route: po Converted to mono-glutamyl form then absorbed in ! proximal jejunum. Excreted in urine & stool.

31 31 Preparations: 1- Synthetic FA (tablets/ parenteral) 2- Folinic acid (5-formyl derivative of THFA, active form).THFA

32 32 FA Deficiency is caused by -Malabsorption & inadequate dietary intake of folate. -Alcohol dependence -Liver Disease. Clinical Pharm: Folate deficiency; megaloblastic anemia. (1 mg po daily): reverse megaloblastic anemia, restore normal serum folate, & replenish body store of folate. -Prophylactically: Pregnant women & patients with hemolytic anemia have increase folate requirements & may become FA-deficient, esp if their diets are marginal. -Maternal FA deficiency: fetal neural tube defect as spina bifida.

33 33 -Patients who require renal dialysis. -Drugs: Methotrexate, trimethoprim & pyrimethamine inhibit DHFRase: deficiency of folate CoFs;; megaloblastic anemia. -Long term use of phenytoin -H risk patients (FA supplementation): pregnancy, premature infants, hemolytic anemia, liver D, & renal dialysis.

34 34 4- Hematopoietic Growth Factors: Glycoprotein hormones regulate ! proliferation & differentiation of hematopoietic progenitor cells in Bone marrow. Produced by recombinant DNA technology.

35 35 Erythropietin : Produced in ! Kidney 1- Epotein: PK: -IV/ SC -T 1/2 : 4-13 hr -Not cleared by dialysis. -Given 2-3 times weekly. 2- Darbepoetin (α): glycosylate form, longer t 1/2.

36 36 Pharmacodynamics: 1- Stimulate erythroid proliferation & differentiation by interacting with specific erythropoietin Rs on RBC progenitors. 2- Induces release of reticulocytes from bone marrow (BM) 3- Tissue hypoxia stimulate erythropoietin synthesis.

37 37 Clinical Pharm/ Uses: 1- Anemia + chronic renal failure Erythropoietin 50-150 IU/kg, IV/SC: improve ! hematocrit (in 10 days) & Hg level (in 2-6 wk) & eliminate ! need for transfusion + Iron & FA. 2- Anemia in HIV patients & zidovudine (anti HIV). 3- Anemia in cancer patients. 4- Anemia due to BM disorders. As in patients with aplastic anemia & other BM failure states, & multiple myeloma. 5- Anemia associated with chronic inflammation (RA) 7- Anemia of prematurity 8- To accelerate erythropoiesis after phlebotomies. 9- Misused by athletes to increase O 2 delivery & performance.

38 38 Adverse effects &Toxicity: 1- Rapid increase of hematocrit & Hg: HTN & thrombosis. 2- Seizure, headache 3- Transient influenza-like syndrome 4- Mild allergic reactions.


Download ppt "1 Antianemeic drugs Agents to Tr anemia Dr Alia Alshanawani."

Similar presentations


Ads by Google